Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 3, 2012, Pages 387-395

  Farkas, Robert ^a   Pozsgai, Eva ^b   Schally, Andrew V ^c   Szigeti, Andras ^a   Szigeti, Edit ^b   Laszlo, Zoltan ^a   Papp, Andras ^a   Gomori, Eva ^a   Mangel, Laszlo ^a   Horvath, Peter O ^a   Bellyei, Szabolcs ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

GHRH R; Hsp90; Neoadjuvant chemoradiotherapy; Prediction of response; Predictive marker of tumor regression; Rectal cancer

Indexed keywords

FLUOROURACIL; FOLIC ACID; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90; HEME BINDING PROTEIN 2; PROTEIN KINASE B; SMALL HEAT SHOCK PROTEIN; SMALL HEAT SHOCK PROTEIN 16.2; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HEBP2 PROTEIN, HUMAN; HEMOPROTEIN; HORMONE RECEPTOR; NEUROPEPTIDE RECEPTOR; PLACENTA PROTEIN; SOMATOTROPIN RELEASING HORMONE RECEPTOR;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CARCINOMA; RECTUM SURGERY; TREATMENT RESPONSE; ADJUVANT THERAPY; CHEMISTRY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RECTUM TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HEAT-SHOCK PROTEINS, SMALL; HEMEPROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PREGNANCY PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859707597     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1110-1     Document Type: Article

References (59)

1. Aoyama A, Steiger RH, Frohli E, Schafer R, von Deimling A, Wiestler OD, Klemenz R (1993) Expression of alpha B-crystallin in human brain tumors. Int J Cancer 55(5):760-764 (Pubitemid 23354890)
2. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, Giovannucci E, Fuchs CS, Ogino S (2010) Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer. doi:10.1002/ cncr.25630
3. Barabutis N, Schally AV (2008) Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer 98(11):1790-1796. doi:10.1038/sj.bjc.6604386 (Pubitemid 351748851)
4. Bardeesy N, De Pinho RA (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2(12):897-909. doi:10.1038/nrc949nrc949 (Pubitemid 37328891)
5. Bellyei S, Szigeti A, Boronkai A, Pozsgai E, Gomori E, Melegh B, Janaky T, Bognar Z, Hocsak E, Sumegi B, Gallyas F Jr (2007a) Inhibition of cell death by a novel 16.2 kD heat shock protein predominantly via Hsp90 mediated lipid rafts stabilization and Akt activation pathway. Apoptosis 12(1):97-112. doi:10.1007/s10495-006-0486-x (Pubitemid 46009507)
6. Bellyei S, Szigeti A, Pozsgai E, Boronkai A, Gomori E, Hocsak E, Farkas R, Sumegi B, Gallyas F Jr (2007b) Preventing apoptotic cell death by a novel small heat shock protein. Eur J Cell Biol 86(3):161-171. doi:10.1016/j.ejcb. 2006.12.004 (Pubitemid 46211196)
7. Berger C, de Muret A, Garaud P, Chapet S, Bourlier P, Reynaud- Bougnoux A, Dorval E, de Calan L, Huten N, le Folch O, Calais G (1997) Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Int J Radiat Oncol Biol Phys 37(3):619-627. doi:S0360301696005779 (Pubitemid 27175318)
8. Bohonowych JE, Gopal U, Isaacs JS (2010) Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol 2010:412985. doi:10.1155/2010/412985
9. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114-1123. doi:10.1056/NEJMoa060829 (Pubitemid 44394918)
10. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P (2002) Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94(4):1121-1130. doi:10.1002/cncr.10327 (Pubitemid 34150868)
11. Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, Armatis P (2002) Inhibition of proliferation in human MNNG/ HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 95(8):1735-1745. doi:10.1002/cncr.10865 (Pubitemid 35153465)
12. Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P, Szepeshazi K (2002) The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA 99(18):11866-11871. doi:10.1073/pnas.1824 33099182433099 (Pubitemid 34994490)
13. Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D'Armiento MR, De Placido S (2009) Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 20(5):906-912. doi:10.1093/annonc/ mdn719
14. Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, Sohn DK, Yoo BC, Lim SB, Kim DH, Ahn JB, Kim IJ, Kim JM, Yoon WH, Park JG (2005) Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol 36(4):364-371. doi:10.1016/j. humpath. 2005.01.018 (Pubitemid 40591806)
15. Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G (2001a) Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J Clin Endocrinol Metab 86(5):2144-2152 (Pubitemid 32472932)
16. Chatzistamou I, Schally AV, Varga JL, Groot K, Busto R, Armatis P, Halmos G (2001b) Inhibition of growth and metastases of MDAMB- 435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs 12(9):761-768 (Pubitemid 33001190)
17. Chung H, Seo S, Moon M, Park S (2008) Phosphatidylinositol-3- kinase/Akt/glycogen synthase kinase-3 beta and ERK1/2 pathways mediate protective effects of acylated and unacylated ghrelin against oxygen-glucose deprivation-induced apoptosis in primary rat cortical neuronal cells. J Endocrinol 198(3):511-521. doi:10.1677/JOE-08-0160
18. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA (2010) Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 76(3):824-830. doi:10.1016/j.ijrobp.2009.02.037
19. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH (2007) Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 109(9):1750-1755. doi:10.1002/cncr.22625 (Pubitemid 46668536)
20. Dhadda AS, Dickinson P, Zaitoun AM, Gandhi N, Bessell EM (2011) Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer. Eur J Cancer. doi:10.1016/j.ejca.2010.12.006
21. Engel JB, Keller G, Schally AV, Toller GL, Groot K, Havt A, Armatis P, Zarandi M, Varga JL, Halmos G (2005) Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab 90(6):3614-3621. doi:10.1210/jc.2004-2179 (Pubitemid 41014334)
22. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon- Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L (2006) Preoperative radiotherapy with or without concurrent Xuorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24(28):4620-4625. doi:10.1200/JCO.2006.06.7629 (Pubitemid 46630960)
23. Gunther K, Dimmler A, Rodel F, Reulbach U, Merkel S, Bittorf BR, Matzel KE, Papadopoulos T, Hohenberger W, Sauer R, Rodel C (2003) P27 does not predict histopathological response to radiochemotherapy in rectal cancer. J Surg Res 113(2):179-188.
24. Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, Szepeshazi K, Koster F, Kovitz K, Groot K, Zarandi M, Kanashiro CA (2005) The expression of the pituitary growth hormonereleasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 102(48): 17424-17429. doi:10.1073/pnas.0506844102 (Pubitemid 41740882)
25. Hermisson M, Strik H, Rieger J, Dichgans J, Meyermann R, Weller M (2000) Expression and functional activity of heat shock proteins in human glioblastoma multiforme. Neurology 54(6):1357-1365
26. Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, Szalontay L, Varga JL, Zarandi M, Halmos G, Vidaurre I, Krishan A, Kurtoglu M, Chandna S, Aigner E, Datz C (2009) GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle 8(19):3149-3156.
27. Holzbeierlein JM, Windsperger A, Vielhauer G (2010) Hsp90: a drug target? Curr Oncol Rep 12(2):95-101. doi:10.1007/s11912-010-0086-3
28. Hwang M, Moretti L, Lu B (2009) HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr Med Chem 16(24):3081-3092
29. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90. doi:10.3322/ caac.20107
30. Kabakov AE, Kudryavtsev VA, Gabai VL (2010) Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med 88(3):241-247. doi:10.1007/s00109-009-0562-0
31. Kahan Z, Varga JL, Schally AV, Rekasi Z, Armatis P, Chatzistamou L, Czompoly T, Halmos G (2000) Antagonists of growth hormone- releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat 60(1):71-79 (Pubitemid 30307467)
32. Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, Fazio VW (2009) Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal Cancer Ann Surg. doi:10.1097/SLA. 0b013e3181b91e63
33. Kiaris H, Schally AV, Varga JL, Groot K, Armatis P (1999) Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci USA 96(26):14894-14898 (Pubitemid 30019736)
34. Kiaris H, Schally AV, Varga JL (2000) Antagonists of growth hormone- releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia 2(3):242-250 (Pubitemid 30346080)
35. Kiaris H, Koutsilieris M, Kalofoutis A, Schally AV (2003) Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormonereleasing hormone antagonists. Expert Opin Investig Drugs 12(8):1385-1394. doi:10.1517/13543784.12.8.1385 (Pubitemid 36949695)
36. Klemenz R, Frohli E, Aoyama A, Hoffmann S, Simpson RJ, Moritz RL, Schafer R (1991) Alpha B crystallin accumulation is a specific response to Ha-ras and v-mos oncogene expression in mouse NIH 3T3 Wbroblasts. Mol Cell Biol 11(2):803-812 (Pubitemid 21895429)
37. Lin LC, Lee HH, Hwang WS, Li CF, Huang CT, Que J, Lin KL, Lin FC, Lu CL (2006) p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 15(4):211-216. doi:10.1016/j.suronc. 2007.01.001 (Pubitemid 46771194)
38. Losi L, Ponti G, Gregorio CD, Marino M, Rossi G, Pedroni M, Benatti P, Roncucci L, de Leon MP (2006) Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract 202(9):663-670. doi:10.1016/j.prp.2006.05.003
39. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11):2680-2686 (Pubitemid 24166250)
40. Mistafa O, Stenius U (2009) Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem Pharmacol 78(9):1115-1126. doi:10.1016/j.bcp.2009.06.016
41. Pollheimer MJ, Kornprat P, Lindtner RA, Harbaum L, Schlemmer A, Rehak P, Langner C (2010) Tumor necrosis is a new promising prognostic factor in colorectal cancer. Hum Pathol 41(12):1749-1757. doi:10.1016/j.humpath.2010.04. 018
42. Pozsgai E, Gomori E, Szigeti A, Boronkai A, Gallyas F Jr, Sumegi B, Bellyei S (2007) Correlation between the progressive cytoplasmic expression of a novel small heat shock protein (Hsp16.2) and malignancy in brain tumors. BMC Cancer 7:233. doi:10.1186/ 1471-2407-7-233
43. Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent- Puig P (2002) Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer 100(2):131-135. doi:10.1002/ijc.10480 (Pubitemid 34666184)
44. Rekasi Z, Czompoly T, Schally AV, Halmos G (2000) Isolation and sequencing of cDNAs for splice variants of growth hormonereleasing hormone receptors from human cancers. Proc Natl Acad Sci USA 97(19):10561-10566. doi:10.1073/pnas.180313297180 313297
45. Rekasi Z, Czompoly T, Schally AV, Boldizsar F, Varga JL, Zarandi M, Berki T, Horvath RA, Nemeth P (2005) Antagonist of growth hormone- releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+ -dependent pathway. Proc Natl Acad Sci USA 102(9):3435-3440. doi:10.1073/pnas.0410 006102 (Pubitemid 40328063)
46. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23(34):8688-8696. doi:10.1200/JCO.2005.02.1329 (Pubitemid 46211512)
47. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731-1740. doi:10.1056/NEJMoa040694 (Pubitemid 39383208)
48. Schally AV, Varga JL (1999) Antagonistic analogs of growth hormone- releasing hormone: new potential antitumor agents. Trends Endocrinol Metab 10(10):383-391.
49. Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z (2000) Peptide analogs in the therapy of prostate cancer. Prostate 45(2):158-166. doi:10.1002/1097-0045(20001001)45:23.0.CO;2-K
50. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G (2001) Hypothalamic hormones and cancer. Front Neuroendocrinol 22(4):248-291. doi:10.1006/frne.2001.0217 (Pubitemid 33010742)
51. Schally AV, Szepeshazi K, Nagy A, Comaru-Schally AM, Halmos G (2004) New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell Mol Life Sci 61(9):1042-1068. doi:10.1007/s00018-004-3434- 3 (Pubitemid 38626508)
52. Schally AV, Varga JL, Engel JB (2008) Antagonists of growth-hormone- releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4(1):33-43. doi:10.1038/ ncpendmet0677 (Pubitemid 350291102)
53. Somji S, Sens MA, Lamm DL, Garrett SH, Sens DA (2001) Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. Cancer Detect Prev 25(1):62-75
54. Suarez J, Vera R, Balen E, Gomez M, Arias F, Lera JM, Herrera J, Zazpe C (2008) Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis 10(6):563-568. doi:10.1111/j.1463-1318.2007.01424.x (Pubitemid 351803062)
55. Sun Y, Mansour M, Crack JA, Gass GL, MacRae TH (2004) Oligomerization, chaperone activity, and nuclear localization of p26, a small heat shock protein from Artemia franciscana. J Biol Chem 279(38):39999-40006. doi:10.1074/jbc. M406999200M4 06999200 (Pubitemid 39258274)
56. Szigeti A, Bellyei S, Gasz B, Boronkai A, Hocsak E, Minik O, Bognar Z, Varbiro G, Sumegi B, Gallyas F Jr (2006) Induction of necrotic cell death and mitochondrial permeabilization by heme binding protein 2/SOUL. FEBS Lett 580(27):6447-6454. doi:10.1016/ j.febslet.2006.10.067 (Pubitemid 44750939)
57. Szigeti A, Hocsak E, Rapolti E, Racz B, Boronkai A, Pozsgai E, Debreceni B, Bognar Z, Bellyei S, Sumegi B, Gallyas F Jr (2010) Facilitation of mitochondrial outer and inner membrane permeabilization and cell death in oxidative stress by a novel Bcl-2 homology 3 domain protein. J Biol Chem 285(3):2140-2151. doi:10.1074/jbc.M109.015222
58. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, Micciche F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F, Coco C (2005) The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 62(3):752-760. doi:10.1016/j.ijrobp.2004.11.017 (Pubitemid 40779765)
59. Zeitler P, Siriwardana G (2002) Antagonism of endogenous growth hormone-releasing hormone (GHRH) leads to reduced proliferation and apoptosis in MDA231 breast cancer cells. Endocrine 18(1):85-90. doi:10.1385/ENDO:18:1:85 (Pubitemid 34828113)